Biopharma ESG Rankings Are Hamstrung by Drug Pricing, Litigation

(Bloomberg) -- At a time when Covid-19 is highlighting drug and vaccine developers’ potential value to society, Barclays in new research this week found many biopharma companies tend to be surprisi...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.